FDA approves Biogen drug for lead genetic cause of infant death

FDA approves Biogen drug for lead genetic cause of infant death


A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in Cambridge, Massachusetts June 18, 2008. The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants.



from Biotech News